MSOS - Verano Holdings: Near-Term Potential Regulatory Change Would Unlock Significant Value
2024-05-09 09:24:55 ET
Summary
- The Department of Justice has recommended that cannabis be rescheduled to a Schedule III drug. Rescheduling will nearly double Verano's FCF given the removal of the 280E tax burden.
- Verano is a leading U.S. cannabis multi-state operator (MSO) and a preferred investment option to benefit from the rescheduling of cannabis given their best-in-class margin profile and undemanding valuation.
- The lack of institutional capital in the cannabis sector and the dominance of retail investors presents a unique opportunity for investors to capitalize on the misunderstood news.
Editor's note: Seeking Alpha is proud to welcome FR Research as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more »
Thesis Overview
On 4/30/24 the Department of Justice (“DOJ”) confirmed after a leak from the Associated Press (“AP”) that they have recommended cannabis be rescheduled from a Schedule 1 to a Schedule III drug. This is arguably the single largest potential catalyst the U.S. cannabis industry has ever seen and will have a profound impact on the entire sector if/once implemented which I believe happens in a few months....
Verano Holdings: Near-Term Potential Regulatory Change Would Unlock Significant Value